Результаты поиска

History of hematopoietic cell transplantation: challenges and progress.

After more than 60 years of research in allogeneic hematopoietic cell transplantation (HCT), this therapy has advanced from one that was declared dead in the 1960s to a standard treatment of otherwise fatal malignant and non-malignant blood diseases. To date, close to 1.5 million hematopoietic cell transplants have been performed in more than 1,500 transplantation centers worldwide. This review will highlight the enormous efforts by numerous investigators throughout the world who have brought the experimental field of HCT to clinical reality, examine ongoing challenges, and provide insights fo

Совпадение в полном тексте источника
… The first grading system for acute GvHD was described in 1974, 42 and the first effective treatment of acute GvHD with anti-thymocyte globulin (ATG) was reported in the same year. 43 In those early years, ATG was not commercially available and the drug was produced in our laboratory by immunizing rabbits … with human thymocytes. …

Developing role of B cells in the pathogenesis and treatment of chronic GVHD.

Chronic graft-versus-host disease (cGVHD) is a major complication affecting the long-term survival of patients after allogeneic haematopoietic stem cell transplantation. The mechanism of cGVHD is unclear, and while previous studies have primarily focused on T cells, the role of B cells in the pathogenesis of cGVHD has been less reported. However, current studies on cGVHD are increasingly focused on the important role of B cells. In this review, we will introduce the newest studies and examine the role of B cells in cGVHD in detail with respect to the following aspects: altered B cell subpopula

I

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… It activates macrophages and stimulates the proliferation of thymocytes. It acts via high-affinity receptors belonging to the haematopoietin receptor superfamily. Interleukin 8 (IL-8) It belongs to chemokines and was originally called neutrophil-activating peptide-1 (NAP-1). … It thus potentiates the proliferation of certain clones of T-helper cells, foetal thymocytes in the presence of IL-2, mast cells after their induction by IL-3 and erythrocytes in cooperation with erythropoietin. It is produced mainly by T H 2-lymphocytes under the influence of IL-1. …

Decoy cells detected in the urine of a patient with complex karyotype Myelodysplastic neoplasms who underwent umbilical cord blood transplantation: a case report.

BACKGROUND: Currently, few literature reports document cases of decoy cells in the urine of umbilical cord blood transplant patients. The majority of the literature indicates that decoy cells are frequently identified in the urine of kidney transplant recipients. CASE PRESENTATION: This case report describes a patient with Myelodysplastic Neoplasms featuring a complex karyotype who underwent umbilical cord blood transplantation. Postoperative urinary cytology revealed decoy cells, and subsequent BK virus nucleic acid testing was positive. However, the routine use of antiviral drugs by the phy

Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article.

Ethiopia is attempting to reduce cancer-related morbidity and mortality through a strategic national cancer control plan but according to Globocan 2020, hematologic malignancies particularly leukemia and non-Hodgkin's lymphoma rank among the top five leading causes of new cancer incidence and cause of death among all age groups in both sexes. Hematopoietic stem-cell transplantation (HSCT) is an advanced treatment modality that makes the only effective treatment for cancer and non-cancer-related hematologic diseases unresponsive to conventional therapy. Patients who need stem cell transplants m

Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature.

Extramedullary multiple myeloma (EMM) is an aggressive sub-entity of multiple myeloma (MM). Despite an excellent improvement in survival for most patients with MM over recent decades, the overall survival (OS) of patients with EMM was usually not longer than 3 years. Standard treatment for patients with EMM has not been established, and their management is particularly challenging. We presented a heavily pretreated young patient with relapsed EMM and refractoriness to a proteasome inhibitor (PI; bortezomib), a next-generation PI (ixazomib), immunomodulatory drugs (IMiDs; lenalidomide), autolog

Tumor buster - where will the CAR-T cell therapy 'missile' go?

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells, and bypass tumor cell apoptosis avoidance mechanisms to some extent. This method has been extensively used to treat hematologic diseases, but the therapeutic effect in solid tumors is not ideal. Tumor antigen escape, treatment-related toxicity, and the immunosuppressive tumor microenvironment (TME

Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: a single-center retrospective analysis.

IntroductionDonor lymphocyte infusion (DLI) can enhance graft-versus-leukemia (GvL) effects following allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric acute myeloid leukemia (AML). However, the optimal integration of azacitidine (Aza) with DLI in children remains uncertain.MethodsWe retrospectively analyzed 16 pediatric AML patients (≤18 years) treated at Fundeni Clinical Institute between 2016 and 2024 who received DLI in combination with azacitidine (75 mg/m2/day for 7 days every 4 weeks) after HSCT. DLI was administered prophylactically or preemptively based on mixed d

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents.

Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor

The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.

Allogeneic hematopoietic cell transplantation (HCT) has transformed over the past several decades through enhanced supportive care, reduced intensity conditioning (RIC), improved human leukocyte antigen (HLA) typing, and novel graft-versus-host disease (GVHD)-prevention and treatment strategies. Most notably, the implementation of post-transplantation cyclophosphamide (PTCy) has dramatically increased the safety and availability of this life-saving therapy. Given reductions in nonrelapse mortality (NRM) with these advances, the HCT community has placed even greater emphasis on developing ways

Selected Abstracts from the 13th Annual Meeting of the Clinical Immunology Society: 2022 Annual Meeting: Immune Deficiency and Dysregulation North American Conference

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Воздействие размера кузова на предклинический тип 1 Диабетное развитие и прогресс.

Тип 1 диабет возникает в результате взаимодействия генетической восприимчивости и воздействия на окружающую среду, что приводит к аутоиммунальному разрушению β-клеток. Хотя медикаментозное лечение (ДМТ) может замедлить переход к клиническому лечению (стадия). 3) тип 1 диабет, реакция на лечение остается непоследовательной и переходной. Обозначенная разнородность типа 1 диабет, формируемый по возрасту, полу, расе или этническому происхождению, а также генетическому происхождению, подчеркивает необходимость разъяснения различных механистических путей. Среди тех, кто оказывает воздействие на окру

LY6E как новый прогнозный биомаркер множественных заболеваний костей, связанных с миеломой.

Остеолитическое заболевание костей, которое ухудшает качество жизни, является распространенным осложнением множественной миеломы (ММ). В этом исследовании мы использовали биоинформатический анализ для выявления дифференциально выраженных генов (DEG), связанных с болезнями костей MM (MBD), из баз данных Gene Express Omnibus (GEO). Здесь кривая Kapan-Meier (K-M) и анализ коксовой регрессии показали, что ключевая молекула лимфоцита антигена 6 Комплекс (LY6E) был тесно связан с продвижением MM, невыгодным прогнозом и образованием MBD. Кроме того, мы подтвердили, что более высокое выражение LI6E сп

Совпадение в полном тексте источника
… LY6E has been demonstrated to exhibit transcriptional activity in a number of organs and tissues such as the lung, liver, uterus, myeloid cells, and thymocytes. Additionally, it is highly expressed in various tumors such as breast, stomach, esophagus, and colorectal 36 . …

Therapeutic potential of single-nucleotide polymorphism-mediated IL6R inhibitors in ankylosing spondylitis treatment.

OBJECTIVE: Interleukin-6 (IL-6) is a multiple-effect cell factor implicated in the etiopathogenesis of several rheumatologic disorders. The blockade of the IL-6 pathway via IL6R inhibitors effectively treats these disorders. However, the clinical significance of the IL6R blockade for ankylosing spondylitis (AS) therapy remains controversial. With advances in genomics, increasing evidence has revealed the role of heritability in the etiology of disease, and Mendelian randomization (MR) analyses are being used more broadly to infer causation. Therefore, this MR study aims to evaluate the potenti

Совпадение в полном тексте источника
… B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. (1988) 167:1253–8. 10.1084/jem.167.3.1253 43. Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M. Characterization of anti-mouse interleukin-6 receptor antibody. …

Current trends of infectious complications following hematopoietic stem cell transplantation in a single center.

This study was to analyze the infectious complications after hematopoietic stem cell transplantation (HSCT) according to the recent changes of HSCT. Medical records of 379 adult patients who underwent HSCT consecutively at Catholic HSCT Center from January 2001 to December 2002 were reviewed retrospectively. Allogeneic HSCT accounted for 75.7% (287/379) and autologous HSCT for 24.3% (92/379). During pre-engraftment period, bacterial infection was predominant, and E. coli was still the most common organism. After engraftment, viral infection was predominant. The incidence of invasive fungal inf

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.

Despite promising clinical results in a small subset of malignancies, therapies based on engineered chimeric antigen receptor and T-cell receptor T cells are associated with serious adverse events, including cytokine release syndrome and neurotoxicity. These toxicities are sometimes so severe that they significantly hinder the implementation of this therapeutic strategy. For a long time, existing preclinical models failed to predict severe toxicities seen in human clinical trials after engineered T-cell infusion. However, in recent years, there has been a concerted effort to develop models, in

Совпадение в полном тексте источника
… For instance, a murine thymocyte culture assay can reproduce the insertions in Lmo2 as well as other T-cell proto-oncogenes (including Mef2c) that functionally associate with developmental arrest and possible transformation. 110 A second assay termed in vitro immortalization assay reports the induction … Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes. Mol Ther 2016;24:1090–9. 10.1038/mt.2016.55 111. Modlich U, Bohne J, Schmidt M, et al. …

MAIT Cells in the Bone Marrow of Patients with Aplastic Anemia.

Mucosal-associated invariant T cells (MAIT cells) are a subset of T cells with innate, effector-like properties that play an essential role in the immune response to microbial infections. In humans, MAIT cells are detectable in the blood, liver, and lungs, but little is known about the frequency of these cells in the bone marrow. Also, the pathogenic role, if any, of MAIT cells in the development of aplastic anemia, a disease with an exquisite origin in the bone marrow, is currently unknown. We investigated the frequency and clinical relevance of bone marrow MAIT cells in a cohort of 14 patien

Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients.

Hematopoietic stem cell transplantation (HSCT) from haploidentical donors is a viable option for patients lacking HLA-matched donors. Here we report the results of a prospective multicenter phase I/II trial of transplantation of TCRαβ and CD19-depleted peripheral blood stem cells from haploidentical family donors after a reduced-intensity conditioning with fludarabine, thiotepa, and melphalan. Thirty pediatric and 30 adult patients with acute leukemia (n = 43), myelodysplastic or myeloproliferative syndrome (n = 6), multiple myeloma (n = 1), solid tumors (n = 6), and non-malignant disorders (n

Genetic Risk Surveillance for Invasive Aspergillosis in Hematology Patients: A Prospective Observational Study.

IntroductionThe association between genetic background and the risk of invasive aspergillosis (IA) has not been addressed in Thailand. We conducted genetic risk surveillance for IA among Thai hematologic patients.MethodsWe conducted a prospective observational cohort study including moderate- to high-risk hematology patients at Ramathibodi Hospital. IA occurrence, relevant clinical data, and genetic analyses were assessed. Odds ratios (ORs) of IA were assessed for the presence of the selected single nucleotide polymorphism genotype using logistic regression.ResultsA total of 357 patients were